Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma-论文-万方医学网

Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma

导出原文传递

翻译打印收藏纠错

作者： Huang, Xiao ^[1] ; Ding, Qingqing ^[2] ; Guo, Hua ^[3] ; Gong, Yun ; Zhao, Jun ; Zhao, Min ; Sui, Dawen ; Wu, Yun ; Chen, Hui ; Liu, Hui ; Zhang, Jinxia ; Resetkova, Erika ; Moulder, Stacy L. ; Wang, Wei-Lien ; Huo, Lei

作者单位： Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85,1515 Holcombe Blvd, Houston, TX 77030 USA ^[1] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA ^[2] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA ^[3]

关键词 PD-L1 Immunohistochemistry 22C3 28-8 SP142 Triple-negative breast cancer

发布时间 2022-09-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除